SLBST is developing a robust therapeutic platform for treatment of endometriosis, based on modulating the inflammatory axis. Our lead candidate (entering Phase 2b trials) is a re-purposing of the well-known immunomodulatory drug HCQ. SLBST has four additional candidates at the pre-clinical stage.
SLBST holds issued US and European method-of-treatment patents for “use of HCQ in an amount appropriate to treat endometriosis”. The company anticipates pursuing both composition-of-matter and method-of-treatment patent claims on its successful pre-clinical candidates.
Our total addressable market is vast with a significant unmet need. Endometriosis affects 1-in-10 women worldwide, including 7.4M women in the US and 13.1M women in Europe. All existing treatments are hormonal, but three-quarters of women surveyed express dissatisfaction. The latest generation of endo therapies, the GnRH antagonists (including elagolix & relugolix), are used by fewer than 20,000 women in the US (or <0.3% of patients). None of the current therapies are compatible with pregnancy.
HCQ has been used for over six decades. It is the standard of care for lupus (SLE) patients and 84% of the 1.4M lupus patients in the US currently take HCQ on a long-term basis. It has an excellent safety and tolerability record when used according to the existing label (despite getting a somewhat tarnished reputation due to reckless off-label covid usage). It is not contra-indicated during pregnancy. Our preclinical work with HCQ for endo was conducted in the 2012-2014 time frame.
Company Details
- Employees
- 9
- Founded
- -
- Address
- St Petersburg, Fl 33702, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.slbstpharma.com/
- Keywords
- Endometriosis, Hydroxychloroquine, HCQ, FemTech.
- HQ
- St Petersburg, FL
Slbst Pharma Questions
Slbst Pharma's website is https://www.slbstpharma.com/
Slbst Pharma's LinkedIn profile is https://www.linkedin.com/company/slbst-pharma
Slbst Pharma has
9 employees.
View email and phone details for 9
employees at Slbst Pharma.
Slbst Pharma's industry is
Pharmaceutical Manufacturing
Slbst Pharma's top competitors are
Ml Cutler & Co., Inc.,
3daughters,
Zucker Law Group Llp,
Mativa Diagnostics,
Advanced Regenerative Manufacturing Institute (Armi) | Biofabusa,
Mansfield Bio-Incubator,
Aipak Pharma,
Jeevan Therapeutics,
Slbst-Inc,
Profounda, Inc..
Slbst Pharma's categories are Pharmaceutical Manufacturing
Slbst Pharma's founding year is 2016
